HCC

TACE and SBRT Followed by Double Immunotherapy for Downstaging Hepatocellular Carcinoma

GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects With Advanced HCC

Personalized Neoantigen Vaccine Plus IL-12 (INO-9012) Versus Active Surveillance in Subjects With High-Risk HCC

Optimizing Y90 Therapy for Radiation Lobectomy

Accumulation of Lipid Droplets as an Underlying Cause of the Progression of Fatty Liver Disease to Liver Cancer

FOG-001 in Locally Advanced or Metastatic Solid Tumors

Partial Immune-boost TACE in unrEseCTable HCC Patients Under Systemic Treatment

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

Multi-analyte Blood Test Clinical Trial

A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib

CEUS vs. AMRI for HCC Detection in Patients With Indeterminate Liver Nodules

Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma

Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC

CXD101 in Immunotherapy-related Liver Cancer

Y-90 Treatment Response Using Transarterial Radioembolization

Effect of the HCC Liver-Link Intervention

SBRT in HCC With Oligoprogression on First-line Immunotherapy

A Study of VRT106, Combined With Camrelizumab, and Apatinib for Advanced HCC

IL1RAP-targeting Chimeric Antigen Receptor T Cells in the Treatment of Relapsed/Refractory Hepatocellular Carcinoma

Pembrolizumab in Hepatocellular Carcinoma